Market news
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
Newsfile Press Release.
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT 2nd Quarter 2026 Financial Results On August 6, 2026, CytoSorbents (NASDAQ: CTSO) released 2 nd quarter financial and operating results. Revenue remained stable at $9.6 million in the 2nd quarter, while profitability continued to improve as the company expanded gross margin to 73%, up from 69% in the prior quarter and 71% a year
Motley Fool Press Release.
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
CytoSorbents Corp (CTSO) slashes cash burn to $200K, boosts gross margins to 73%, and advances DrugSorb ATR and Hemodefen BGA regulatory pathways despite STAR-T trial setback.
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.